S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
Climate bill: Could coal communities shift to nuclear?
MUST WATCH: Unusual 3-second financial maneuver (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
Climate bill: Could coal communities shift to nuclear?
MUST WATCH: Unusual 3-second financial maneuver (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
Climate bill: Could coal communities shift to nuclear?
MUST WATCH: Unusual 3-second financial maneuver (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
Is Apple Pointing to a Massive Recession in the U.S.? (Ad)
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
Climate bill: Could coal communities shift to nuclear?
MUST WATCH: Unusual 3-second financial maneuver (Ad)
NASDAQ:DXCM

DexCom - DXCM Stock Forecast, Price & News

$89.83
+1.59 (+1.80%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$87.60
$89.90
50-Day Range
$67.99
$91.40
52-Week Range
$66.89
$164.86
Volume
1.91 million shs
Average Volume
3.15 million shs
Market Capitalization
$35.27 billion
P/E Ratio
187.15
Dividend Yield
N/A
Price Target
$112.30

DexCom MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.93 Rating Score
Upside/​Downside
25.0% Upside
$112.30 Price Target
Short Interest
Healthy
3.09% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.76
Upright™ Environmental Score
News Sentiment
0.47mentions of DexCom in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$410,644 Sold Last Quarter
Proj. Earnings Growth
40.51%
From $0.79 to $1.11 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.04 out of 5 stars

Medical Sector

25th out of 1,117 stocks

Surgical & Medical Instruments Industry

3rd out of 113 stocks

DXCM stock logo

About DexCom (NASDAQ:DXCM) Stock

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

DexCom Trading Up 1.8 %

NASDAQ:DXCM opened at $89.83 on Friday. The stock has a fifty day moving average price of $78.92 and a two-hundred day moving average price of $94.89. The stock has a market capitalization of $35.27 billion, a price-to-earnings ratio of 187.15, a PEG ratio of 3.59 and a beta of 1.03. The company has a debt-to-equity ratio of 0.87, a quick ratio of 4.30 and a current ratio of 4.72. DexCom has a 1 year low of $66.89 and a 1 year high of $164.86.

DexCom (NASDAQ:DXCM - Get Rating) last released its quarterly earnings data on Thursday, July 28th. The medical device company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.02). The business had revenue of $696.20 million during the quarter, compared to analysts' expectations of $709.33 million. DexCom had a return on equity of 11.79% and a net margin of 7.47%. The company's revenue was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.19 EPS. As a group, sell-side analysts anticipate that DexCom will post 0.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Piper Sandler cut their target price on shares of DexCom from $120.00 to $110.00 and set an "overweight" rating on the stock in a research note on Friday, July 29th. Morgan Stanley cut their target price on shares of DexCom from $91.00 to $83.00 and set an "equal weight" rating on the stock in a research note on Friday, July 29th. SVB Leerink cut their target price on shares of DexCom from $141.25 to $125.00 in a research note on Friday, April 29th. BTIG Research lowered their price target on DexCom from $135.00 to $105.00 and set a "buy" rating for the company in a report on Friday, June 24th. Finally, Canaccord Genuity Group lowered their price target on DexCom from $131.25 to $125.00 in a report on Friday, April 29th. Two research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $115.23.

Insiders Place Their Bets

In other news, Director Steven Robert Pacelli sold 250 shares of the firm's stock in a transaction on Tuesday, May 24th. The stock was sold at an average price of $296.33, for a total value of $74,082.50. Following the completion of the transaction, the director now owns 35,175 shares in the company, valued at $10,423,407.75. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, Director Steven Robert Pacelli sold 250 shares of the firm's stock in a transaction on Tuesday, May 24th. The stock was sold at an average price of $296.33, for a total value of $74,082.50. Following the completion of the transaction, the director now owns 35,175 shares in the company, valued at $10,423,407.75. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Jereme M. Sylvain sold 600 shares of the firm's stock in a transaction on Monday, June 6th. The shares were sold at an average price of $301.57, for a total value of $180,942.00. Following the completion of the transaction, the chief financial officer now owns 17,408 shares of the company's stock, valued at approximately $5,249,730.56. The disclosure for this sale can be found here. Over the last quarter, insiders sold 2,850 shares of company stock worth $410,645. 0.41% of the stock is owned by corporate insiders.

Receive DXCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.

DXCM Stock News Headlines

2 Growth Stocks That Just Hit Setbacks: Are They Buys?
DexCom (NASDAQ:DXCM) Stock Rating Reaffirmed by Cowen
Oppenheimer Cuts DexCom (NASDAQ:DXCM) Price Target to $105.00
DexCom (NASDAQ:DXCM) PT Lowered to $100.00
DexCom (NASDAQ:DXCM) Shares Gap Down After Earnings Miss
Why DexCom Stock Is Falling Today
See More Headlines
Receive DXCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.

DXCM Company Calendar

Last Earnings
7/28/2022
Today
8/13/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:DXCM
CUSIP
25213110
Employees
7,000
Year Founded
1999

Price Target and Rating

Average Stock Price Forecast
$112.30
High Stock Price Forecast
$163.75
Low Stock Price Forecast
$83.00
Forecasted Upside/Downside
+25.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
14 Analysts

Profitability

Net Income
$154.70 million
Pretax Margin
5.49%

Debt

Sales & Book Value

Annual Sales
$2.45 billion
Cash Flow
$0.97 per share
Book Value
$5.75 per share

Miscellaneous

Free Float
390,972,000
Market Cap
$35.27 billion
Optionable
Optionable
Beta
1.03

Social Links















DXCM Stock - Frequently Asked Questions

Should I buy or sell DexCom stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There are currently 1 hold rating and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DXCM shares.
View DXCM analyst ratings
or view top-rated stocks.

What is DexCom's stock price forecast for 2022?

14 Wall Street research analysts have issued 1-year target prices for DexCom's stock. Their DXCM share price forecasts range from $83.00 to $163.75. On average, they expect the company's share price to reach $112.30 in the next twelve months. This suggests a possible upside of 25.0% from the stock's current price.
View analysts price targets for DXCM
or view top-rated stocks among Wall Street analysts.

How have DXCM shares performed in 2022?

DexCom's stock was trading at $134.2375 at the start of the year. Since then, DXCM stock has decreased by 33.1% and is now trading at $89.83.
View the best growth stocks for 2022 here
.

When is DexCom's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our DXCM earnings forecast
.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) released its earnings results on Thursday, July, 28th. The medical device company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.19 by $0.02. The medical device company earned $696.20 million during the quarter, compared to the consensus estimate of $709.33 million. DexCom had a net margin of 7.47% and a trailing twelve-month return on equity of 11.79%. The firm's revenue for the quarter was up 17.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.19 earnings per share.
Read the conference call transcript
.

When did DexCom's stock split?

DexCom shares split on the morning of Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly created shares were distributed to shareholders after the closing bell on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

What guidance has DexCom issued on next quarter's earnings?

DexCom issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.86 billion-$2.91 billion, compared to the consensus revenue estimate of $2.92 billion.

What is Kevin Sayer's approval rating as DexCom's CEO?

347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees.

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP).

What is DexCom's stock symbol?

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

Who are DexCom's major shareholders?

DexCom's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (4.61%), Sands Capital Management LLC (4.56%), Jennison Associates LLC (2.18%), Clearbridge Investments LLC (1.45%), Northern Trust Corp (0.99%) and Brown Advisory Inc. (0.87%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Chad Patterson, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends
.

How do I buy shares of DexCom?

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DexCom's stock price today?

One share of DXCM stock can currently be purchased for approximately $89.83.

How much money does DexCom make?

DexCom (NASDAQ:DXCM) has a market capitalization of $35.27 billion and generates $2.45 billion in revenue each year. The medical device company earns $154.70 million in net income (profit) each year or $0.48 on an earnings per share basis.

How many employees does DexCom have?

The company employs 7,000 workers across the globe.

Does DexCom have any subsidiaries?

The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.
Read More

When was DexCom founded?

DexCom was founded in 1999.

How can I contact DexCom?

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.dexcom.com. The medical device company can be reached via phone at (858) 200-0200, via email at investorrelations@dexcom.com, or via fax at 858-200-0201.

This page (NASDAQ:DXCM) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.